Investigation of Factors Influencing the Effectiveness of Deformable Nanovesicles for Insulin Nebulization Inhalation
-
Published:2024-06-29
Issue:7
Volume:16
Page:879
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Yu Jinghan1, Meng Yingying1, Wen Zhiyang1, Jiang Yu1, Guo Yiyue2, Du Simeng1, Liu Yuling1, Xia Xuejun1
Affiliation:
1. Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China 2. Beijing Wehand-Bio Pharmaceutical Co., Ltd., Beijing 102600, China
Abstract
Nebulized inhalation offers a noninvasive method for delivering drugs to treat both local respiratory and systemic diseases. In this study, insulin was used as a model drug to design a series of deformable nanovesicles (DNVs) with key quality attributes, including particle size, deformability, and drug load capacity. We investigated the effects of these properties on aerosol generation, macrophage phagocytosis, and bloodstream penetration. The results showed that deformability improved nebulization performance and reduced macrophage phagocytosis, benefiting local and systemic delivery. However, the advantage of DNVs for transmembrane penetration was not evident in the alveolar epithelium. Within the size range of 80–490 nm, the smaller the particle size of IPC-DNVs, the easier it is to evade clearance by macrophages and the more effective the in vivo hypoglycemic efficacy will be. In the drug load range of 3–5 mg/mL, a lower drug load resulted in better hypoglycemic efficacy. The area above the blood glucose decline curve with time (AAC) of nebulized DNVs was 2.32 times higher than that of the insulin solution, demonstrating the feasibility and advantages of DNVs in the pulmonary delivery of biomacromolecule drugs. This study provides insights into the construction and formulation optimization of pulmonary delivery carriers.
Funder
the Medical and Health Science and Technology Innovation Project of the Chinese Academy of Medical Sciences
Reference44 articles.
1. Peng, S., Wang, W., Zhang, R., Wu, C., Pan, X., and Huang, Z. (2024). Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives. Pharmaceutics, 16. 2. Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review;Feng;Int. J. Nanomed.,2024 3. Viegas, C., Patrício, A.B., Prata, J.M., Nadhman, A., Chintamaneni, P.K., and Fonte, P. (2023). Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review. Pharmaceutics, 15. 4. Inhaled Lipid Nanoparticles Alleviate Established Pulmonary Fibrosis;Li;Small,2023 5. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease;Shirley;Drugs,2019
|
|